Collaboration is a vital pillar of our strategy for developing first-in-class immunotherapy for solid tumors. We believe that collaboration is key to achieving a “cure for cancer.” We welcome partnership opportunities around our technology platforms and product pipeline.
Discovery to Licensing
Our lead antibody program ESK1, targeting Wilms’ Tumor 1 (WT1), was out-licensed to Novartis for further development. ESK1 was discovered in collaboration with Memorial Sloan-Kettering Cancer Center. We are also working with Boehringer Ingelheim on a research collaboration for the identification of antibodies recognizing intracellular proteins.
We have established strategic partnerships with Memorial Sloan-Kettering Cancer Center for the joint discovery and research of novel antibodies to address some of the most challenging cancer indications. Eureka supports academic research and the sharing of our advanced T cell engineering technologies, which address the issues facing current CART technology platforms.